Sequence Analysis and Comparison of the Key Genes of Domestic Live Attenuated Varicella Vaccine.
10.3881/j.issn.1000-503X.2017.05.007
- Author:
Ya-Ru QUAN
1
;
Zhen CHEN
1
;
Ping QIU
1
;
Xiao-Yu CUI
1
;
Chang-Gui LI
1
;
Li-Yong YUAN
1
Author Information
1. Division of Respiratory Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control,Beijing 100050,China.
- Publication Type:Journal Article
- From:
Acta Academiae Medicinae Sinicae
2017;39(5):637-642
- CountryChina
- Language:English
-
Abstract:
Objective To analyze the safety and consistency of domestic live attenuated varicella vaccines (LAVVs) at gene level.Methods The key genes (ORF38,ORF54,and ORF62) of LAVVs produced by four Chinese manufacturers were amplified by polymerase chain reaction (PCR) and sequenced.The sequencing results were compared with the sequences of Dumas,P-Oka,and V-Oka strains in GenBank and with the sequences of Varilrix (GSK) and Varivax (Merck).Results The ORF38 and ORF54 gene sequences of four domestic LAVVs were the same as each other and completely consistent with the sequences of V-Oka and Varilrix;however,it was different from Varivax (Merck) at one site.The ORF62 gene sequences of four domestic LAVVs were similar,and had individual nucleotide differences with V-Oka,Varilrix(GSK),and Varivax (Merck).Conclusions The sequences of ORF38,ORF54,and ORF62 of four domestic LAVVs are almost the same,showing good stability.They have small differences with V-Oka,Varilrix(GSK),and Varivax (Merck),without introducing new mutations.
